| (1) |
Ries LAG, Eisner MP, Kosary CL, et al. 2000 SEER
cancer statistics review, 1973-1997. Bethesda, MD: National Cancer Institute. |
| (2) |
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. 1998
ANational Cancer Data Base report on 53, 856 cases of thyroid carcinoma
treated in the US, 1985-1995. Cancer. 83: 2638-2648. |
| (3) |
Mazzaferri EL, Jhiang SM. 1994 Long-term impact
of initial surgical and medical therapy on papillary and follicular thyroid
cancer. Am J Med. 97: 418-428. |
| (4) |
Schlumberger MJ. 1999 Diagnostic follow-up of
well-differentiated thyroid carcinoma: historical perspective and current
status. J Endocrinol Invest. 22(Suppl 11): 3-7. |
| (5) |
Kitamura Y, Shimizu K, Nagahama M, et al. 1999
Immediate causes of death in thyroid carcinoma: clinicopathological analysis
of 161 fatal cases. J Clin Endocrinol Metab. 84: 4043-4049. |
| (6) |
Mazzaferri EL. 1999 NCCN thyroid carcinoma practice
guidelines. 1999 oncology, vol 13, supplement no. 11A, NCCN proceedings.
13: 391-442. (Guidelines may be accessed at http://www.nccn.org/guidelines.htm;
last accessed on 3/6/2001.) |
| (7) |
Akslen LA, LiVolsi VA. 2000 Prognostic significance
of histologic grading compared with subclassification of papillary thyroid
carcinoma. Cancer. 88: 1902-1908. |
| (8) |
DeGroot LJ, Kaplan EL, Straus FH, Shukla MS. 1994 Does the method
of management of papillary thyroid carcinoma make a difference in outcome?
World J Surg. 18: 123-130. |
| (9) |
American Joint Committee on Cancer. 1992 Head
and neck tumors. Thyroid gland. In: Beahrs OH, Henson DE, Hutter RVP, Myers
MH, eds. Manual for staging of cancer. Philadelphia: J. B. Lippincott; 53-54. |
| (10) |
Cady B, Sedgwick CE, Meissner WA, Wool MS, Salzman FA, Werber J. 1979
Risk factor analysis in differentiated thyroid cancer. Cancer. 43: 810-820. |
| (11) |
Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger
M. 2000 Is diagnostic iodine-131 scanning useful after total thyroid
ablation for differentiated thyroid cancer? J Clin Endocrinol Metab. 85:
175-178. |
| (12) |
Sherman SI, Brierley JD, Sperling M, et al. 1998
Prospective multicenter study of thyroid carcinoma treatment-initial analysis
of staging and outcome. Cancer. 83: 1012-1021. |
| (13) |
Hundahl SA, Cady B, Cunningham MP, et al. 2000
Initial results from a prospective cohort study of 5583 cases of thyroid
carcinoma treated in the United States during 1996. U.S. and German Thyroid
Cancer Study Group. An American College of Surgeons Commission on Cancer
Patient Care Evaluation study. Cancer. 89: 202-217. |
| (14) |
Van De Velde CJH, Hamming JF, Goslings BM, et al.
1988 Report of the consensus development conference on the management
of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oncol.
24: 287-292. |
| (15) |
Baldet L, Manderscheid JC, Glinoer D, Jaffiol C,
Coste Seignovert B, Percheron C. 1989 The management of differentiated
thyroid cancer in Europe in 1988. Results of an international survey. Acta
Endocrinol(Copenh). 120: 547-558. |
| (16) |
Solomon BL, Wartofsky L, Burman KD. 1996 Current trends in the
management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol
Metab. 81: 333-339. |
| (17) |
Farahati J, Reiners C, Stuschke M, et al. 1996
Differentiated thyroid cancer- Impact of adjuvant external radiotherapy
in patients with perithyroidal tumor infiltration(stage pT4). Cancer. 77:
172-180. |
| (18) |
Tsang TW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK,
Sutcliffe SB. 1998 The effects of surgery, radioiodine, and external
radiation therapy on the clinical outcome of patients with differentiated
thyroid carcinoma. Cancer. 82: 375-388. |
| (19) |
Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz
MK, Sutcliffe SB. 1988 Papillary and follicular thyroid cancer: impact
of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 14: 1063-1075. |
| (20) |
Bennedbaek FN, Hegedus L. 2000 Management of
the solitary thyroid nodule: results of a North American survey. J Clin
Endocrinol Metab. 85: 2493-2498. |
| (21) |
Ortiz R, Hupart KH, DeFesi CR, Surks MI. 1998
Effect of early referral to an endocrinologist on efficiency and cost of
evaluation and development of treatment plan in patients with thyroid nodules.
J Clin Endocrinol Metab. 83: 3803-3807. |
| (22) |
Cholewinski SP, Yoo KS, Klieger PS, O'Mara RE. 2000 Absence of
thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
J Nucl Med. 41: 1198-1202. |
| (23) |
Maxon HR, Englaro EE, Thomas SR, et al. 1992
Radioiodine-131 therapy for well-differentiated thyroid cancer-a quantitative
radiation dosimetric approach: outcome and validation in 85 patients. J
Nucl Med. 33: 1132-1136. |
| (24) |
Cady B, Hay ID, Shaha AR, Clark OH, Rossi R, Dudley N. 1998 Unilateral
total lobectomy: is it sufficient surgical treatment for patients with AMES
low-risk papillary thyroid carcinoma? Discuss Surg. 124: 964-966. |
| (25) |
Cady B. 1997 Our AMES is true: how an old concept
still hits the mark-or, risk group assignment points the arrow to rational
therapy selection in differentiated thyroid cancer. Am J Surg. 174: 462-468. |
| (26) |
Shaha AR, Loree TR, Shah JP. 1995 Prognostic
factors and risk group analysis in follicular carcinoma of the thyroid.
Surgery. 118: 1131-1138. |
| (27) |
Mazzaferri EL. 1993 Thyroid carcinoma. Papillary
and follicular. In: Mazzaferri EL, Samaan N, eds. Endocrine tumors. Cambridge:
Blackwell Scientific Publications Inc.; 278-333. |
| (28) |
Hay ID, Grant CS, Taylor WF, McConahey WM. 1987 Ipsilateral lobectomy
versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective
analysis of surgical outcome using a novel prognostic scoring system. Surgery.
102:1088-1095. |
| (29) |
Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger
FA, Bacourt F. 1984 Pulmonary metastases in differentiated thyroid carcinoma.
Study of 58 cases with implications for the primary tumor treatment. Cancer.
53: 982-992. |
| (30) |
Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA. 1998
Unilateral total lobectomy: is it sufficient surgical treatment for patients
with AMES low-risk papillary thyroid carcinoma? Surgery. 124: 958-966. |
| (31) |
Mirallie E, Visset J, Sagan C, Hamy A, Le Bodic MF,
Paineau J. 1999 Localization of cervical node metastasis of papillary
thyroid carcinoma. World J Surg. 23: 970-973. |
| (32) |
Scheumann GFW, Gimm O, Wegener G, Hundeshagen H,
Dralle H. 1994 Prognostic significance and surgical management of locoregional
lymph node metastases in papillary thyroid cancer. World J Surg. 18: 559-568. |
| (33) |
Mazzaferri EL. 1991 Treating differentiated thyroid
carcinoma: where do we draw the line? Mayo Clin Proc. 66: 105-111. |
| (34) |
Schlumberger MJ. 1998 Medical progress-papillary and follicular
thyroid carcinoma. N Engl J Med. 338: 297-306. |
| (35) |
Newman KD, Black T, Heller G, et al. 1998 Differentiated
thyroid cancer: determinants of disease progression in patients, 21 years
of age at diagnosis-a report from the Surgical Discipline Committee of the
Children's Cancer Group. Ann Surg. 227: 533-541. |
| (36) |
Miccoli P, Antonelli A, Spinelli C, Ferdeghini M, Fallahi P, Baschieri
L. 1998 Completion total thyroidectomy in children with thyroid cancer
secondary to the Chernobyl accident. Arch Surg. 133: 89-93. |
| (37) |
La Quaglia MP, Black T, Holcomb III GW, et al. 2000
Differentiated thyroid cancer: clinical characteristics, treatment, and
outcome in patients under 21 years of age who present with distant metastases.
A report from the Surgical Discipline Committee of the Children's Cancer
Group [In Process Citation]. J Pediatr Surg. 35: 955-959. |
| (38) |
Nishida T, Nakao K, Hashimoto T. 2000 Local control in differentiated
thyroid carcinoma with extrathyroidal invasion. Am J Surg. 179: 86-91. |
| (39) |
Baudin E, Travagli JP, Ropers J, et al. 1998
Microcarcinoma of the thyroid gland-The Gustave-Roussy Institute Experience.
Cancer. 83: 553-559. |
| (40) |
Moosa M, Mazzaferri EL. 1997 Occult thyroid carcinoma. Cancer.
10: 180-188. |
| (41) |
Lin HS, Komisar A, Opher E, Blaugrund SM. 1999
Surgical management of thyroid masses: assessing the need for frozen section
evaluation. Laryngoscope. 109: 868-873. |
| (42) |
Goldman JM, Line BR, Aamodt RL, Robbins J. 1980 Influence of triiodothyronine
withdrawal time on 131-I uptake postthyroidectomy for thyroid cancer. J
Clin Endocrinol Metab. 50: 734-739. |
| (43) |
Burmeister LA, duCret RP, Mariash CN. 1991 Local
reactions to radioiodine in the treatment of thyroid cancer. Am J Med. 90:
217-222. |
| (44) |
Mazzaferri EL. 2000 Carcinoma of follicular epithelium: radioiodine
and other treatment outcomes. In: Braverman LE, Utiger RD, eds. The thyroid:
a fundamental and clinical text. Philadelphia: Lippincott Willams & Wilkins;
904-929. |
| (45) |
Pasieka JL, Thompson NW, McLeod MK, Burney RE, Macha
M. 1992 The incidence of bilateral well-differentiated thyroid cancer
found at completion thyroidectomy. World J Surg. 16: 711-716. |
| (46) |
Scheumann GFW, Seeliger H, Musholt TJ, et al. 1996 Completion thyroidectomy
in 131 patients with differentiated thyroid carcinoma. Eur J Surg. 162:
677-684. |
| (47) |
Dralle H, Gimm O, Simon D, et al. 1998 Prophylactic
thyroidectomy in 75 children and adolescents with hereditary medullary thyroid
carcinoma: German and Austrian experience. World J Surg. 22: 744-751. |
| (48) |
Udelsman R, Lakatos E, Ladenson P. 1996 Optimal surgery for papillary
thyroid carcinoma. World J Surg. 20: 88-93. The impact of initial surgical
management on outcome in young patients with differentiated thyroid cancer.
J Pediatr Surg. 33: 1134-1138. |
| (49) |
Pattou F, Combemale F, Fabre S, et al. 1998 Hypocalcemia following
thyroid surgery: incidence and prediction of outcome. World J Surg. 22:
718-724. |
| (50) |
Robie DK, Dinauer CW, Tuttle RM, et al. 1998 The impact of initial
surgical management on outcome in young patients with differentiated thyroid
cancer. J Pediatr Surg. 33: 1134-1138. |
| (51) |
Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. 1998
The importance of surgeon experience for clinical and economic outcomes
from thyroidectomy. Ann Surg. 228: 320-328. |
| (52) |
Lamade W, Renz K, Willeke F, Klar E, Herfarth C. 1999 Effect of
training on the incidence of nerve damage in thyroid surgery. Br J Surg.
86: 388-391. |
| (53) |
Hay ID. 1990 Papillary thyroid carcinoma. Endocrinol Metab Clin
North Am. 19: 545-576. |
| (54) |
Mazzaferri EL. 1997 Thyroid remnant 131I ablation for papillary
and follicular thyroid carcinoma. Thyroid. 7: 265-271. |
| (55) |
Vassilopoulou-Sellin R, Klein MJ, Smith TH, et al. 1993 Pulmonary
metastases in children and young adults with differentiated thyroid cancer.
Cancer. 71: 1348-1352. |
| (56) |
Spencer CA, Takeuchi M, Kazarosyan M, et al. 1998 Serum thyroglobulin
autoantibodies: Prevalence, influence on serum thyroglobulin measurement,
and prognostic significance in patients with differentiated thyroid carcinoma.
J Clin Endocrinol Metab. 83: 1121-1127. |
| (57) |
Schlumberger M, Mancusi F, Baudin E, Pacini F. 1997 131-I therapy
for elevated thyroglobulin levels. Thyroid. 7: 273-276. |
| (58) |
Wartofsky L, Sherman SI, Gopal J, Schlumberger M, Hay ID. 1998
The use of radioactive iodine in patients with papillary and follicular
thyroid cancer. J Clin Endocrinol Metab. 83: 4195-4199. |
| (59) |
Sugg SL, Ezzat S, Rosen IB, Freeman JL, Asa SL. 1998 Distinct multiple
RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J
Clin Endocrinol Metab. 83: 4116-4122. |
| (60) |
Grunwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ. 1996 Prognostic
value of thyroglobulin after thyroidectomy before ablative radioiodine therapy
in thyroid cancer. J Nucl Med. 37: 1962-1964. |
| (61) |
Schlumberger M. 1998 Use of radioactive iodine in patients with
papillary and follicular thyroid cancer: towards a selective approach. J
Clin Endocrinol Metab. 83: 4201-4203. |
| (62) |
Taylor T, Specker B, Robbins J, et al. 1998 Outcome after treatment
of high-risk papillary and non-Hu rthle cell follicular thyroid carcinoma.
Ann Intern Med. 129: 622-627. |
| (63) |
Krishnamurthy GT, Blahd WH. 1977 Radioiodine I-131 therapy in the
management of thyroid cancer. A prospective study. Cancer. 40: 195-202. |
| (64) |
DeGroot LJ, Kaplan EL, McCormick M, Straus FH. 1990 Natural history,
treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol
Metab. 71: 414-424. |
| (65) |
Brierley J, Maxon HR. 1998 Radioiodine and external radiation therapy.
In: Fagin JA, ed. Thyroid cancer. Boston/Dordrecht London: Kluwer Academic
Publishers; 285-317. |
| (66) |
Grigsby PW, Siegel BA, Baker S, Eichling JO. 2000 Radiation exposure
from outpatient radioactive iodine(131-I) therapy for thyroid carcinoma.
J Am Med Assoc. 283: 2272-2274. |
| (67) |
DeGroot LJ, Reilly M. 1982 Comparison of 30-and 50-mCi doses of
iodine-131 for thyroid ablation. Ann Intern Med. 96: 51-53. |
| (68) |
Beierwaltes WH, Rabbani R, Dmuchowski C, Lloyd RV, Eyre P, Mallette
S. 1984 An analysis of "ablation of thyroid remnants" with I-131 in
511 patients from 1947-1984: experience at University of Michigan. J Nucl
Med. 25: 1287-1293. |
| (69) |
Doi SA, Woodhouse NJ. 2000 Ablation of the thyroid
remnant and 131-I dose in differentiated thyroid cancer. Clin Endocrinol(Oxf).
52: 765-773. |
| (70) |
Bal C, Padhy AK, Jana S, Pant GS, Basu AK. 1996 Prospective randomized
clinical trial to evaluate the optimal dose of 131I for remnant ablation
in patients with differentiated thyroid carcinoma. Cancer. 77: 2574-2580. |
| (71) |
Hodgson DC, Brierley JD, Tsang RW, Panzarella T. 1998 Prescribing
131iodine based on neck uptake produces effective thyroid ablation and reduced
hospital stay. Radiother Oncol. 47: 325-330. |
| (72) |
Johansen K, Woodhouse NJ, Odugbesan O. 1991 Comparison of 1073
MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid
tissue in patients with differentiated thyroid cancer. J Nucl Med. 32: 252-254. |
| (73) |
Oskam R, Rijksen G, Lips CJ, Staal GE. 1985 Enolase isozymes in
differentiated and undifferentiated medullary thyroid carcinomas. Cancer.
55: 394-399. |
| (74) |
Park HM, Perkins OW, Edmondson JW, Schnute RB, Manatunga A. 1994
Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131.
Thyroid. 4: 49-54. |
| (75) |
Leger FA, Izembart M, Dagousset F, et al. 1998 Decreased uptake
of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging
for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med.
25: 242-246. |
| (76) |
Muratet JP, Daver A, Minier JF, Larra F. 1998 Influence of scanning
doses of iodine-131 on subsequent first ablative treatment outcome in patients
operated on for differentiated thyroid carcinoma. J Nucl Med. 39: 1546-1550. |
| (77) |
Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F. 1997
Predicting the efficacy of first iodine-131 treatment in differentiated
thyroid carcinoma. J Nucl Med. 38: 1362-1368. |
| (78) |
Haugen BR, Pacini F, Reiners C, et al. 1999 A comparison of recombinant
human thyrotropin and thyroid hormone withdrawal for the detection of thyroid
remnant or cancer. J Clin Endocrinol Metab. 84: 3877-3885. |
| (79) |
Greenler DP, Klein HA. 1989 The scope of false-positive iodine-131
images for thyroid carcinoma. Clin Nucl Med. 14: 111-117. |
| (80) |
Mitchell G, Pratt BE, Vini L, McCready VR, Harmer CL. 2000 False
positive 131I whole body scans in thyroid cancer. Br J Radiol. 73: 627-635. |
| (81) |
Chung JK, Lee YJ, Jeong JM, et al. 1997 Clinical significance of
hepatic visualization on iodine-131 whole-body scan in patients with thyroid
carcinoma. J Nucl Med. 38: 1191-1195. |
| (82) |
Nemec J, Zamrazil V, Pohunkova D,Rohling S. 1979 Radioiodide treatment
of pulmonary metastases of differentiated thyroid cancer. Results and prognostic
factors. Nuklearmedizin. 18: 86-90. |
| (83) |
Schlumberger M, Tubiana M, De Vathaire F, et al. 1986 Long-term
results of treatment of 283 patients with lung and bone metastases from
differentiated thyroid carcinoma. J Clin Endocrinol Metab. 63: 960-967. |
| (84) |
Samaan NA, Schultz PN, Haynie TP, Ordonez NG. 1985 Pulmonary metastasis
of differentiated thyroid carcinoma: treatment results in 101 patients.
J Clin Endocrinol Metab. 60: 376-380. |
| (85) |
Lazar V, Bidart JM, Caillou B, et al. 1999 Expression of the Na1/I2
symporter gene in human thyroid tumors: a comparison study with other thyroidspecific
genes. J Clin Endocrinol Metab. 84: 3228-3234. |
| (86) |
Jhiang SM, Cho JY, Ryu K-Y, et al. 1998 An immunohistochemical
study of Na1/I-symporter in human thyroid tissues and salivary gland tissues.
Endocrinology. 139: 4416-4419. |
| (87) |
Venkataraman GM, Yatin M, Marcinek R, Ain KB. 1999 Restoration
of iodide uptake in dedifferentiated thyroid carcinoma: relationship to
human Na1/I-symporter gene methylation status. J Clin Endocrinol Metab.
84: 2449-2457. |
| (88) |
Maruca J, Santner S, Miller K, Santen RJ. 1984 Prolonged iodine
clearance with a depletion regimen for thyroid carcinoma: concise communication.
J Nucl Med. 25: 1089-1093. |
| (89) |
Lakshmanan M, Schaffer A, Robbins J, Reynolds J, Norton J. 1988
A simplified low iodine diet in I-131 scanning and therapy of thyroid cancer.
Clin Nucl Med. 2: 866-868. |
| (90) |
Guljord L. 2000 Collection of low-iodine recipes, ed 2. ThyCa:
Thyroid Cancer Survivors' Association (http://www.thyca.org/;
last accessed September 16, 2000). |
| (91) |
Maxon HR. 1999 Quantitative radioiodine therapy in the treatment
of differentiated thyroid cancer. Q J Nucl Med. 43: 313-323. |
| (92) |
Samaan NA, Schultz PN, Hickey RC, Haynie TP, Johnston DA, Ordonez NG.
1992 Well-differentiated thyroid carcinoma and the results of various
modalities of treatment. A retrospective review of 1599 patients. J Clin
Endocrinol Metab. 75: 714-720. |
| (93) |
Reynolds JC. 1994 Comparison of I-131 absorbed radiation doses
in children and adults: a tool for estimating therapeutic I-131 doses in
children. In: Robbins J, ed. Treatment of thyroid cancer in childhood. Springfield,
VA: U.S. Department of Commerce, Technology Administration, National Technical
Information Service; 127-135. |
| (94) |
Benua RS, Cicale NR, Sonenberg M, et al. 1962 The relation of radioiodine
dosimetry to results and complications in the treatment of metastatic thyroid
cancer. Am J Roentgenal. 87: 171-178. |
| (95) |
Leeper RD. 1973 The effect of 131 I therapy on survival of patients
with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol
Metab. 36: 1143-1152. |
| (96) |
Van Nostrand D, Neutze J, Atkins F. 1986 Side effects of "rational
dose" iodine-131 therapy for metastatic well-differentiated thyroid carcinoma.
J Nucl Med. 27: 1519-1527. |
| (97) |
Bushnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE. 1992 Complications,
sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl
Med. 33: 2214-2221. |
| (98) |
Koong SS, Reynolds JC, Movius EG, et al. 1999 Lithium as a potential
adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma.
J Clin Endocrinol Metab. 84: 912-916. |
| (99) |
Grunwald F, Menzel C, Bender H, et al. 1998 Redifferentiation therapyinduced
radioiodine uptake in thyroid cancer. J Nucl Med. 39: 1903-1906. |
| (100) |
Datz FL. 1986 Cerebral edema following iodine-131 therapy for thyroid
carcinoma metastatic to the brain. J Nucl Med. 27: 637-640. |
| (101) |
Maxon III H, Smith HS. 1990 Radioiodine-131 in the diagnosis and
treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab
Clin North Am. 19: 685-718. |
| (102) |
Chiu AC, Delpassand ES, Sherman SI. 1997 Prognosis and treatment
of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 82: 3637-3642. |
| (103) |
Levenson D, Gulec S, Sonenberg M, Lai E, Goldsmith SJ, Larson SM. 1994
Peripheral facial nerve palsy after high-dose radioiodine therapy in patients
with papillary thyroid carcinoma. Ann Intern Med. 120: 576-578. |
| (104) |
Maxon HR, Thomas SR, Hertzberg VS, et al. 1983 Relation between
effective radiation dose and outcome of radioiodine therapy for thyroid
cancer.NEngl J Med. 309: 937-941. |
| (105) |
Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM. 1998 Intermediate
and long-term side effects of high-dose radioiodine therapy for thyroid
carcinoma. J Nucl Med. 39: 1551-1554. |
| (106) |
Raymond JP, Izembart M, Marliac V, et al. 1989 Temporary ovarian
failure in thyroid cancer patients after thyroid remnant ablation with radioactive
iodine. J Clin Endocrinol Metab. 69: 186-190. |
| (107) |
Maxon III H. 1993 The role of I-131 in the treatment of thyroid
cancer. Thyroid Today. 16: 1-9. |
| (108) |
Schlumberger M, De Vathaire F, Ceccarelli C, et al. 1996 Exposure
to radioactive iodine-131 for scintigraphy or therapy does not preclude
pregnancy in thyroid cancer patients. J Nucl Med. 37: 606-612. |
| (109) |
Edmonds CJ, Smith T. 1986 The long-term hazards of the treatment
of thyroid cancer with radioiodine. Br J Radiol. 59: 45-51. |
| (110) |
Ceccarelli C, Battisti P, Gasperi M, et al. 1999 Radiation dose
to the testes after 131I therapy for ablation of postsurgical thyroid remnants
in patients with differentiated thyroid cancer. J Nucl Med. 40: 1716-1721. |
| (111) |
Handelsman DJ, Turtle JR. 1983 Testicular damage after radioactive
iodine (I-131) therapy for thyroid cancer. Clin Endocrinol. 18: 465-472. |
| (112) |
Pacini F, Gasperi M, Fugazzola L, et al. 1994 Testicular function
in patients with differentiated thyroid carcinoma treated with radioiodine.
J Nucl Med. 35: 1418-1422. |
| (113) |
Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. 1976 Subsequent
fertility and birth histories of children and adolescents treated with 131I
for thyroid cancer. J Nucl Med. 17: 460-464. |
| (114) |
Wong JB, Kaplan MM, Meyer KB, Pauker SG. 1990 Ablative radioactive
iodine therapy for apparently localized thyroid carcinoma. A decision analytic
perspective. Endocrinol Metab Clin North Am. 19: 741-760. |
| (115) |
De Vathaire F, Schlumberger M, Delisle MJ, et al. 1997 Leukaemias
and cancers following iodine-131 administration for thyroid cancer. Br J
Cancer. 75: 734-739. |
| (116) |
Hall P, Holm L-E. 1995 Cancer in iodine-131 exposed patients. J
Endocrinol Invest. 18: 147-149. |
| (117) |
Leeper RD, Shimaoka K. 1980 Treatment of metastatic thyroid cancer.
Clin Endocrinol Metab. 9: 383-406. |
| (118) |
Maheshwari YK, Hill Jr CS, Haynie 3rd TP, Hickey RC, Samaan NA. 1981
131I therapy in differentiated thyroid carcinoma: M. D. Anderson Hospital
experience. Cancer. 47: 664-671. |
| (119) |
Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. 1984 Radioiodine
treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience.
Br J Radiol. 57: 323-327. |
| (120) |
Moosa M, Mazzaferri EL. 1997 Outcome of differentiated thyroid
cancer diagnosed in pregnant women. J Clin Endocrinol Metab. 82: 2862-2866. |
| (121) |
Pacini F, Lari R, Mazzeo S, Grasso L, Taddei D, Pinchera A. 1985
Diagnostic value of a single serum thyroglobulin determination on and off
thyroid suppressive therapy in the follow-up of patients with differentiated
thyroid cancer. Clin Endocrinol. 23: 405-411. |
| (122) |
Ladenson PW, Braverman LE, Mazzaferri EL, et al. 1997 Comparison
of administration of recombinant human thyrotropin with withdrawal of thyroid
hormone for radioactive iodine scanning in patients with thyroid carcinoma.
N Engl J Med. 337: 888-896. |
| (123) |
Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ.
1994 Serum thyroglobulin in the follow-up of patients with treated differentiated
thyroid cancer. J Clin Endocrinol Metab. 79: 98-105. |
| (124) |
Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A. 1999 Value
of the first serum thyroglobulin level after total thyroidectomy for the
diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl
Med. 26: 1448-1452. |
| (125) |
Ringel M, Ladenson P, Levine MA. 1998 Molecular diagnosis of residual
and recurrent thyroid cancer by amplification of thyroglobulin messenger
ribonucleic acid in peripheral blood. J Clin Endocrinol Metab. 83: 4435-4442. |
| (126) |
Torrens JI, Burch HB. 1996 Serum thyroglobulin measurement: utility
in clinical practice. Endocrinologist. 6: 125-144. |
| (127) |
Grigsby PW, Baglan K, Siegel BA. 1999 Surveillance of patients
to detect recurrent thyroid carcinoma. Cancer. 85: 945-951. |
| (128) |
Spencer CA, Takeuchi M, Kazarosyan M. 1996 Current status and performance
goals for serum thyroglobulin assays. Clin Chem. 42: 164-173. |
| (129) |
Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C. 1987
Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid
cancer patients with detectable serum thyroglobulin levels. J Nucl Med.
28: 1888-1891. |
| (130) |
Pineda JD, Lee T, Ain K, Reynolds J, Robbins J. 1995 Iodine-131
therapy for thyroid cancer patients with elevated thyroglobulin and negative
diagnostic scan. J Clin Endocrinol Metab. 80: 1488-1492. |
| (131) |
Mazzaferri EL. 1995 Treating high thyroglobulins with radioiodine.
A magic bullet or a shot in the dark? J Clin Endocrinol Metab. 80: 1485-1487. |
| (132) |
Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. 1996
Degree of thyrotropin suppression as a prognostic determinant in differentiated
thyroid cancer. J Clin Endocrinol Metab. 81: 4318-4323. |
| (133) |
Cooper DS, Specker B, Ho M, et al. 1999 Thyrotropin suppression
and disease progression in patients with differentiated thyroid cancer:
results from the National Thyroid Cancer Treatment Cooperative Registry.
Thyroid. 8: 737-744. |
| (134) |
Kamel N, Gullu S, Dagci IS, et al. 1999 Degree of thyrotropin suppression
in differentiated thyroid cancer without recurrence or metastases. Thyroid.
9: 1245-1248. |